Skip to main content

Advertisement

SpringerLink
Log in

HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

An Erratum to this article was published on 07 October 2010

Abstract

Proto-oncogene HER2 (also known as erbB-2 or neu) plays an important role in the carcinogenesis and the prognosis of breast cancer. Many epidemiological studies have been conducted to explore the association between the HER2 Ile655Val polymorphism and breast cancer risk. However, inconsistency existed in the results. Therefore, we performed a meta-analysis of 27 published case–control studies including 11,504 cases and 12,538 controls. We assessed the strength of the association by crude odds ratios (ORs) with 95% confidence intervals (CIs) and reached a result that HER2 Ile655Val polymorphism was associated with an increased breast cancer risk in overall populations (for Ile/Val vs. Ile/Ile: OR = 1.05, 95% CI = 1.00–1.12, P = 0.07 for heterogeneity; for the dominant model Ile/Val + Val/Val vs. Ile/Ile: OR = 1.10, 95% CI = 1.01–1.20, P = 0.01 for heterogeneity). In subgroup analysis by ethnicity, we found a significant association among Africans (for Val/Val vs. Ile/Ile: OR = 8.78, 95% CI = 1.94–39.72, P = 0.35 for heterogeneity; for the recessive model Val/Val vs. Ile/Val +Ile/Ile: OR = 8.60, 95% CI = 1.92–38.48, P = 0.31 for heterogeneity) and Asians (for Ile/Val vs. Ile/Ile: OR = 1.18, 95% CI = 1.01–1.39, P = 0.41 for heterogeneity; for the dominant model Val/Val + Ile/Val vs. Ile/Ile: OR = 1.18, 95% CI = 1.01–1.38, P = 0.27 for heterogeneity). In conclusion, our meta-analysis suggests that HER2 Ile 655Val polymorphism may contribute to breast cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165–184

    PubMed  Google Scholar 

  2. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167

    Article  CAS  PubMed  Google Scholar 

  3. Porter-Jordan K, Lippman ME (1994) Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 8:73–100

    CAS  PubMed  Google Scholar 

  4. De Placido S, Carlomagno C, De Laurentiis M, Bianco AR (1998) c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat 52:55–64

    Article  PubMed  Google Scholar 

  5. Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791–808

    Article  CAS  PubMed  Google Scholar 

  6. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11–31

    Article  CAS  PubMed  Google Scholar 

  7. Siegel PM, Dankort DL, Hardy WR, Muller WJ (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068–7077

    CAS  PubMed  Google Scholar 

  8. Papewalis J, Nikitin A, Rajewsky MF (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19:5452

    Article  CAS  PubMed  Google Scholar 

  9. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412–417

    Article  CAS  PubMed  Google Scholar 

  10. Baxter SW, Campbell IG (2001) Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:557–559

    Article  CAS  PubMed  Google Scholar 

  11. Wang-Gohrke S, Chang-Claude J (2001) Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:1657–1659

    Article  CAS  PubMed  Google Scholar 

  12. Hishida A, Hamajima N, Iwata H, Matsuo K, Hirose K, Emi N, Tajima K (2002) Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94:1807–1808

    CAS  PubMed  Google Scholar 

  13. Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37–41

    Article  CAS  PubMed  Google Scholar 

  14. Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, Campbell IG (2003) The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prev 12:1109–1111

    CAS  PubMed  Google Scholar 

  15. Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY, Geradts J, Iacocca M, Cowan D, Conway K, Dressler L (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79:355–364

    Article  CAS  PubMed  Google Scholar 

  16. Kamali-Sarvestani E, Talei AR, Merat A (2004) Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215:83–87

    CAS  PubMed  Google Scholar 

  17. Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76:260–263

    Article  CAS  PubMed  Google Scholar 

  18. Pinto D, Vasconcelos A, Costa S, Pereira D, Rodrigues H, Lopes C, Medeiros R (2004) HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 13:177–181

    Article  CAS  PubMed  Google Scholar 

  19. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65

    Article  CAS  PubMed  Google Scholar 

  20. An HJ, Kim NK, Oh D, Kim SH, Park MJ, Jung MY, Kang H, Kim SG, Lee KP, Lee KS (2005) Her2 genotype and breast cancer progression in Korean women. Pathol Int 55:48–52

    Article  CAS  PubMed  Google Scholar 

  21. Nelson SE, Gould MN, Hampton JM, Trentham-Dietz A (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:R357–R364

    Article  CAS  PubMed  Google Scholar 

  22. Cox DG, Hankinson SE, Hunter DJ (2005) The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics 15:447–450

    Article  CAS  PubMed  Google Scholar 

  23. Frank B, Hemminki K, Wirtenberger M, Bermejo JL, Bugert P, Klaes R, Schmutzler RK, Wappenschmidt B, Bartram CR, Burwinkel B (2005) The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 26:643–647

    Article  CAS  PubMed  Google Scholar 

  24. Zubor P, Vojvodova A, Danko J, Kajo K, Szunyogh N, Lasabova Z, Biringer K, Visnovsky J, Dokus K, Galajda P, Plank L (2006) HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 53:49–55

    CAS  PubMed  Google Scholar 

  25. Benusiglio PR, Lesueur F, Luccarini C, Conroy DM, Shah M, Easton DF, Day NE, Dunning AM, Pharoah PD, Ponder BA (2005) Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7:R204–R209

    Article  CAS  PubMed  Google Scholar 

  26. Papadopoulou E, Simopoulos K, Tripsianis G, Tentes I, Anagnostopoulos K, Sivridis E, Galazios G, Kortsaris A (2007) Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma 54:365–373

    CAS  PubMed  Google Scholar 

  27. Tommasi S, Fedele V, Crapolicchio A, Bellizzi A, Paradiso A, Reshkin SJ (2003) ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. Int J Mol Med 12:131–134

    CAS  PubMed  Google Scholar 

  28. Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy NK (2008) TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87

    Article  CAS  PubMed  Google Scholar 

  29. Siddig A, Mohamed AO, Kamal H, Awad S, Hassan AH, Zilahi E, Al-Haj M, Bernsen R, Adem A (2008) HER-2/neu Ile655Val polymorphism and the risk of breast cancer. Ann N Y Acad Sci 1138:84–94

    Article  PubMed  Google Scholar 

  30. Mutluhan H, Akbas E, Erdogan NE, Soylemez F, Senli MS, Polat A, Helvaci I, Seyrek E (2008) The influence of HER2 genotypes as molecular markers on breast cancer outcome. DNA Cell Biol 27:575–579

    Article  CAS  PubMed  Google Scholar 

  31. Lee SC, Hou MF, Hsieh PC, Wu SH, Hou LA, Ma H, Tsai SM, Tsai LY (2008) A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin Biochem 41:121–125

    Article  CAS  PubMed  Google Scholar 

  32. Naidu R, Yip CH, Taib NA (2008) Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma 55:87–95

    CAS  PubMed  Google Scholar 

  33. Kallel I, Kharrat N, Al-fadhly S, Rebai M, Khabir A, Boudawara TS, Rebai A HER2 polymorphisms and breast cancer in Tunisian women. Genet Test Mol Biomarkers 14:29-35

  34. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O’Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300–310

    PubMed  Google Scholar 

  35. Wang Z, Fu Y, Tang C, Lu S, Chu WM (2009) SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls. Breast Cancer Res Treat. doi:10.1007/s10549-009-0648-y

    Google Scholar 

  36. Wang Z, Cui D, Lu W (2010) NBS1 8360G> C polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. doi:10.1007/s10549-010-0772-8

    Google Scholar 

  37. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826

    CAS  PubMed  Google Scholar 

  38. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  CAS  PubMed  Google Scholar 

  39. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    CAS  PubMed  Google Scholar 

  40. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    CAS  PubMed  Google Scholar 

  41. Casalini P, Iorio MV, Galmozzi E, Menard S (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200:343–350

    Article  CAS  PubMed  Google Scholar 

  42. Stern DF (2003) ErbBs in mammary development. Exp Cell Res 284:89–98

    Article  CAS  PubMed  Google Scholar 

  43. Troyer KL, Lee DC (2001) Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 6:7–21

    Article  CAS  PubMed  Google Scholar 

  44. Bargmann CI, Hung MC, Weinberg RA (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657

    Article  CAS  PubMed  Google Scholar 

  45. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578–10582

    Article  CAS  PubMed  Google Scholar 

  46. Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 99:15937–15940

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, 30006, Tianjin, China

    Su Lu, Hong Liu & Xishan Hao

  2. Key Laboratory of Cancer prevention and Therapy, 30006, Tianjin, China

    Su Lu, Hong Liu & Xishan Hao

  3. Second Department of Breast Tumor, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China

    Su Lu, Hong Liu & Xishan Hao

  4. Department of Epidemiology and Biostatistics, Nanjing Medical University, 210029, Nanjing, China

    Zhanwei Wang

Authors
  1. Su Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhanwei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xishan Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hong Liu or Xishan Hao.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s10549-010-1196-1

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, S., Wang, Z., Liu, H. et al. HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies. Breast Cancer Res Treat 124, 771–778 (2010). https://doi.org/10.1007/s10549-010-0886-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-0886-z

Keywords

Search

Navigation